This study aims to assess relapse-free survival (RFS) and OS in patients with resected early-stage NSCLC with rare targetable driver mutations, including EGFR Exon20 insertion, KRAS G12C, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping, RET, and ERBB2 mutations. Here, ALK is linked to non-small cell lung carcinoma.